The livestream starts on 18 November 2021 at 16:30 CETWelcome and introduction16:30 – 16:40Schnell O (Munich, Germany)Living evidence and guidance in diabetes – The future of guideline creation? 16:40 – 17:00 Vandvik PO (Oslo, Norway) CGM in diabetes: Which studies designs are relevant for living guidelines?17:00 – 17:20 Battelino T (Ljubljana, Slovenia)Pilot projects of the Guideline Workshop – Key learnings for guidelines in diabetes and CVD17:20 – 17:40 Marx N (Aachen, Germany) Innovative strategies for the creation of CKD Guidelines 17:40 – 18:00 Brosius F (Tucson, USA)COVID-19 and diabetes: Guidelines and learnings from DARE18:00 – 18:20 Kosiborod M (Kansas City, USA)Discussion 18:20 – 18:40 Break18:40 – 19:00Understanding biosimilar insulins19:00 – 19:20Vilsbøll T (Copenhagen, Denmark)Insulin treatment: A perspective on new outcomes 19:20 – 19:40 Forst T (Mannheim, Germany)Novel glucose metrics - Towards accepted outcomes in diabetes 19:40 – 20:00Bergenstal R (Minneapolis, USA)Discussion20:00 – 20:20See you on Friday, 19 November 2021 at 08:30 CETCardiovascular Outcome Trials: a new perspective on Number Needed to Treated (NNT)08:30 – 08:45Guerci B (Vandoeuvre Lès Nancy, France)Cardiorenal risk in type 2 diabetes - Should we treat to prevent?08:45 – 09:00Itzhak B (Haifa, Israel)Cardiovascular prevention in diabetes: Current strategies with Aspirine09:00 – 09:15 Santilli F (Chieti, Italy) Diabetes therapies: Mechanisms of action in the heart09:15 – 09:30 Carr R (London, UK) Discussion09:30 – 10:00 Break10:00 – 10:30ESC heart failure Guidelines: What´s new? Implementation in clinical practice10:30 – 10:50 Rosano GP (Padova, Italy)SGLT-2 inhibition in HFrEF and HFpEF – New outcomes10:50 – 11:10Boehm M (Homburg/Saar, Germany)Discussion11:10 – 11:30 Finerenone - New outcomes in chronic kidney disease and type 2 diabetes 11:30 – 11:50 Rossing P (Copenhagen, Denmark) Future perspectives of MRAs 11:50 – 12:10 Heerspink H (Groningen, Netherlands) Discussion12:10 – 12:30 Break12:30 – 13:00One year on from DAPA-CKD13:00 – 13:20Chair: Wanner C (Wuerzburg, Germany), Heerspink H (Groningen, Netherlands)Renal outcomes with GLP-1 RAs 13:20 – 13:40Giorgino F (Bari, Italy)Discussion13:40 – 14:00 SGLT2 inhibitors, MRAs and GLP1-RAs: The next decade14:00 – 14:30 Boehm M (Homburg/Saar, Germany)
Ceriello A (Milano, Italy)
Giorgino F (Bari, Italy)
Heerspink H (Groningen, Netherlands)
Lehrke M (Aachen, Germany)
Rosano G (Padova, Italy)
Rossing P (Copenhagen, Denmark)
Wanner C (Wuerzburg, Germany)Break14:30 – 15:00CVOTs in GLP1-RA: The power of individual endpoints15:00 – 15:20Nauck M (Bochum, Germany) Dual GIP/GLP1-RAs – Outcomes and future perspectives 15:20 – 15:40 Wysham C (Rockwood, US) Obesity and NASH: Novel treatment options 15:40 – 16:00 Blueher M (Leipzig, Germany)Discussion16:00 – 16:15Industry´s perspective - panel discussion 16:15 – 17:15Oral Presentations 17:15 – 18:15Chair: Standl E (Munich, Germany) Abstract awards and closing18:15 – 18:45Schnell O (Munich, Germany)Thank you for your attendance and your contribution to the Virtual CVOT Summit 2021. See you next year!We will be right back.We are currently having some technical issues. We will be right back.
Log in with email address and password.
Forgot password?
To log in you need to create a password:
